Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
517 stopped studies mapped to Malignant Liver Neoplasm and descendants · 92% state a reason
Over the 517 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT03563274 | QuiremSpheres Observational Study(Hope166) | — | terminated | Jun 20, 2018 | Terumo Europe N.V. | did not meet planned recruitment expectations with a slow recruitment rate | Enrollment / accrual |
| NCT04404647 | Irreversible Electroporation of Unresectable Liver Tumors | N/A | withdrawn | May 27, 2020 | Ole Thorlacius-Ussing, MD, DMSc, Professor of Surgery | Low accrual rate | Enrollment / accrual |
| NCT04526080 | Intrabucally Administered Electromagnetic Fields Versus Placebo as Third-line Therapy For…(TheraBionics) | Phase 2 | withdrawn | Aug 25, 2020 | Wake Forest University Health Sciences | This application needs further attention in terms of FDA approval and will be reassigned under a… | Other (stated, no rule matched) |
| NCT03303469 | Hypoxic Changes in Hepatocellular Carcinoma (HCC) Following Trans Arterial Chemo… | Phase 2 | terminated | Oct 6, 2017 | University of Alabama at Birmingham | study was terminated due to poor enrollment | Enrollment / accrual |
| NCT02129322 | Effect of Adjuvant Therapy by Sorafenib, Oxaliplatin and S-1 | Phase 2 | withdrawn | May 2, 2014 | Zhejiang University | patients not enrolled | Enrollment / accrual |
| NCT02460991 | A Study of ONCO-DOX in Locally Advanced Hepatocellular Carcinoma(SOLACE) | Phase 3 | terminated | Jun 3, 2015 | Boston Scientific Corporation | Slow enrollment | Enrollment / accrual |
| NCT03008512 | A Phase II Study of Weekly Genexol-PM in Patients With Hepatocelluar Carcinoma After… | Phase 2 | terminated | Jan 2, 2017 | Gachon University Gil Medical Center | Poor accrual | Enrollment / accrual |
| NCT04398927 | Systemic Chemotherapy Plus PD-1 for Metastasis ICC | Phase 2 | withdrawn | May 22, 2020 | Sun Yat-sen University | no patient enrolled | Enrollment / accrual |
| NCT02524119 | LEE001 and Chemoembolization In Patients With Advanced Hepatocellular Carcinoma(LEE001) | Phase 2 | terminated | Aug 14, 2015 | University of Texas Southwestern Medical Center | This study was terminated after the sponsor withdrew our support | Other (stated, no rule matched) |
| NCT03215355 | Improving CBCT for Liver IG-SBRT Using Gadoxetate Disodium | Phase 4 | withdrawn | Jul 12, 2017 | Slawa Cwajna | Not approved | Other (stated, no rule matched) |
| NCT03219372 | Pravastatin Intervention to Delay Hepatocellular Carcinoma Recurrence | Phase 2 | terminated | Jul 17, 2017 | Cedars-Sinai Medical Center | Study discontinued due to low accrual. | Enrollment / accrual |
| NCT00823290 | Sorafenib and LBH589 in Hepatocellular Carcinoma (HCC) | Phase 1 | terminated | Jan 15, 2009 | University of Erlangen-Nürnberg Medical School | Investigator left site | Investigator |
| NCT00503867 | SIR-Spheres® for the Treatment of Unresectable Hepatocellular Carcinoma | N/A | terminated | Jul 19, 2007 | Sirtex Medical | Low patient recruitment | Enrollment / accrual |
| NCT03040453 | Immunological Response After Ablative Therapy in the Liver(IRAL) | N/A | withdrawn | Feb 2, 2017 | Karolinska Institutet | poor recruitment | Enrollment / accrual |
| NCT03063840 | Microwave Ablation for the Treatment of Malignant Liver Tumors Closed to Intrahepatic… | N/A | withdrawn | Feb 24, 2017 | National Taiwan University Hospital | NO participants enrolled | Enrollment / accrual |
| NCT04270461 | NKG2D-based CAR T-cells Immunotherapy for Patient With r/r NKG2DL+ Solid Tumors | Phase 1 | withdrawn | Feb 17, 2020 | Jiujiang University Affiliated Hospital | Study is withdrawn because of administrative reasons | Other (stated, no rule matched) |
| NCT03484962 | Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced… | Phase 2 | withdrawn | Apr 2, 2018 | Fuda Cancer Hospital, Guangzhou | No participants enrolled | Enrollment / accrual |
| NCT02558205 | Correlation Between CT Perfusion and Post Y-90 TARE PET/CT Dosimetry | — | withdrawn | Sep 23, 2015 | Rush University Medical Center | unable to rectuir | Other (stated, no rule matched) |
| NCT02029690 | Ph 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With…(TRAP) | Phase 1 | terminated | Jan 8, 2014 | Polaris Group | not stated | Not stated |
| NCT02966223 | A Study to Assess the Effect of Y-90 Therapy on Non-target/Background Liver | N/A | terminated | Nov 17, 2016 | Indiana University | Sponsor prematurely withdrew financial support. | Funding |
| NCT04044326 | The Safety and Efficacy of Spherical Microwave Ablation for the Treatment of Malignant… | N/A | withdrawn | Aug 5, 2019 | National Taiwan University Hospital | Machine cannot provide | Other (stated, no rule matched) |
| NCT04546802 | HepATocellular Cancer Hcv Therapy Study(HATCHeT) | Phase 3 | withdrawn | Sep 14, 2020 | Bayside Health | Recruitment will be too difficult due to available PBS funded treatment and recent Australian… | Enrollment / accrual |
| NCT03203837 | Biomarker Analyses in Hepatocellular Carcinoma (HCC) Patients Treated With TheraSphere® | — | terminated | Jun 29, 2017 | Northwestern University | Funding Discontinued due to low accrual rate | Enrollment / accrual |
| NCT03644511 | Use of Sorafenib and/or Regorafenib in Liver Cancer (Hepatocellular Carcinoma) Subsequent…(SORAGO-HCC) | — | terminated | Aug 23, 2018 | Bayer | The interest of potential centers is very limited. | Other (stated, no rule matched) |
| NCT03172559 | Radiotherapy Versus no Intervention in Adult Patients With Hepatocellular Carcinoma Not…(RADBRI) | N/A | withdrawn | Jun 1, 2017 | University Health Network, Toronto | Investigator decided not to pursue the study due to other competing studies. | Investigator |
| NCT00020774 | SCH 66336 With or Without Gemcitabine Followed by Surgery Compared With Surgery Alone in… | Phase 2 | withdrawn | Apr 13, 2004 | Jonsson Comprehensive Cancer Center | not stated | Not stated |
| NCT03511222 | Vorolanib (X-82) Combined With Checkpoint Inhibitors in Patients With Solid Tumors | Phase 1 | terminated | Apr 27, 2018 | Washington University School of Medicine | Low accrual | Enrollment / accrual |
| NCT04395118 | STOP HCC: Mailed HCV Treatment Outreach Program for HCC Prevention for Elevated LFTs(STOP-HCC) | N/A | withdrawn | May 20, 2020 | University of Texas Southwestern Medical Center | Study will not be conducted as a RCT due to limited project timeline. | Other (stated, no rule matched) |
| NCT02989870 | Sorafenib and Bavituximab Plus SBRT in Unresectable Hepatocellular Carcinoma | Phase 1 | withdrawn | Dec 12, 2016 | H. Lee Moffitt Cancer Center and Research Institute | No Interest. Investigator was unable to enroll any participants on study. | Investigator |
| NCT03480152 | Messenger RNA (mRNA)-Based, Personalized Cancer Vaccine Against Neoantigens Expressed by… | Phase 1 / Phase 2 | terminated | Mar 29, 2018 | National Cancer Institute (NCI) | slow accrual | Enrollment / accrual |
| NCT03801499 | Lenvatinib for Unresectable Intrahepatic Cholangiocarcinoma | Phase 2 | withdrawn | Jan 11, 2019 | Sun Yat-sen University | Protocol modification | Other (stated, no rule matched) |
| NCT04093648 | T Cells co- Expressing a Second Generation Glypican 3-specific Chimeric Antigen Receptor… | Phase 1 | withdrawn | Sep 18, 2019 | Baylor College of Medicine | The key elements of this study were incorporated into another study. | Other (stated, no rule matched) |
| NCT01486134 | Major RF Ablations of Hepatomas Under MR Thermometry Monitoring(ARMTICH) | N/A | terminated | Dec 6, 2011 | Assistance Publique - Hôpitaux de Paris | For technical reasons | Other (stated, no rule matched) |
| NCT03075553 | Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma | Phase 2 | terminated | Mar 9, 2017 | Mayo Clinic | due to poor response | Other (stated, no rule matched) |
| NCT02013778 | Phase 1-2 Trial HCQ Plus TACE in Unresectable HCC | Phase 1 / Phase 2 | terminated | Dec 17, 2013 | Abramson Cancer Center at Penn Medicine | Lack of enrollment | Enrollment / accrual |
| NCT03748927 | Natural History Study of Children and Adults With Fibrolamellar Hepatocellular Carcinoma | — | withdrawn | Nov 21, 2018 | National Cancer Institute (NCI) | slow/insufficient accrual | Enrollment / accrual |
| NCT03990974 | Postoperative Antimicrobial Prophylaxis Versus Placebo for Infection Prevention in HCC…(HCC) | Phase 3 | suspended | Jun 19, 2019 | Sun Yat-sen University | There were difficulties in implementation | Other (stated, no rule matched) |
| NCT04025567 | Vancomycin in Patients With Unresectable Fibrolamellar Hepatocellular Carcinoma (FLC) Oral | Phase 2 | withdrawn | Jul 19, 2019 | National Cancer Institute (NCI) | slow/insufficient accrual. | Enrollment / accrual |
| NCT01760616 | Huaier Granule for Prevention of Disease Progression of Hepatocarcinoma After Non-radical… | Phase 4 | terminated | Jan 4, 2013 | Qidong Gaitianli Medicines Co., Ltd | difficult to recruit patients | Enrollment / accrual |
| NCT03079778 | Transarterial Chemoembolization (TACE) With or Without Stereotactic Body Radiotherapy…(TACERT) | N/A | withdrawn | Mar 14, 2017 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Opened up a separate Clinicaltrials.gov trial form, study ID TACE | Other (stated, no rule matched) |
| NCT02580253 | Adjuvant Chemotherapy Based on the Adenosine Triphosphate Tumor Chemosensitivity Assay… | Phase 2 | withdrawn | Oct 20, 2015 | Zhejiang University | no patients enrolled | Enrollment / accrual |
| NCT02867280 | Sorafenib Treatment in Patients With Hepatocellular Carcinoma With Microvascular Invasion… | Phase 3 | terminated | Aug 15, 2016 | Sun Yat-sen University | Midterm analysis showed negative results. | Other (stated, no rule matched) |
| NCT03217253 | Tazemetostat in Treating Patients With Metastatic or Unresectable Solid Tumors or B-Cell… | Phase 1 | withdrawn | Jul 14, 2017 | National Cancer Institute (NCI) | Other - Drug Manufacturer decision to close study | Drug supply |
| NCT03267940 | Study of PEGPH20 With Cisplatin (CIS) and Gemcitabine (GEM); PEGPH20 With Atezolizumab… | Phase 1 | terminated | Aug 31, 2017 | Halozyme Therapeutics | Sponsor decision | Sponsor / business decision |
| NCT01923233 | In-Situ Therapeutic Cancer Vaccine for Refractory Liver Cancer | Phase 1 / Phase 2 | withdrawn | Aug 15, 2013 | Mirror Biologics, Inc. | interventional radiologist suffered stroke and unable to perform RFA procedure | Other (stated, no rule matched) |
| NCT01995227 | An Individualized Anti-Cancer Vaccine Study in Patients With HCC | Phase 1 / Phase 2 | withdrawn | Nov 26, 2013 | Mirror Biologics, Inc. | Study site change to Thailand | Other (stated, no rule matched) |
| NCT02289300 | A Study to Evaluate a Study Drug, DCB-BO1202, for Alleviating Liver Fibrosis in Liver… | Phase 2 | withdrawn | Nov 13, 2014 | A2 Healthcare Taiwan Corporation | At sponsor's discretion | Other (stated, no rule matched) |
| NCT04044651 | Lenvatinib Plus Nivolumab Versus Lenvatinib for Advanced Hepatocellular Carcinoma With… | Phase 2 / Phase 3 | withdrawn | Aug 5, 2019 | Shi Ming | Bristol-Myers Squibb company terminated this study | Sponsor / business decision |
| NCT03382886 | Nivolumab and Bevacizumab in Patients With Advanced and or Metastatic Hepatocellular…(NUANCE) | Phase 1 | terminated | Dec 26, 2017 | University of Utah | PI decided to terminate due to low/slow accrual | Enrollment / accrual |
| NCT03433703 | Trial to Evaluate Safety and Efficacy of Treatment of Physician Choice (TPC) Following… | Phase 2 | terminated | Feb 14, 2018 | Eisai Inc. | Study recruitment was stopped due to difficulty in enrolling the targeted number of participants. | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Mar 29, 2021source: clinicaltrials